Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 2.71%
- Poor long term growth as Net Sales has grown by an annual rate of -2.51% and Operating profit at -237.28% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
The company has declared Negative results for the last 13 consecutive quarters
3
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,875 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.82
-28.57%
1.90
Revenue and Profits:
Net Sales:
131 Million
(Quarterly Results - Jun 2025)
Net Profit:
-42 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
37.13%
0%
37.13%
6 Months
42.4%
0%
42.4%
1 Year
33.83%
0%
33.83%
2 Years
6.46%
0%
6.46%
3 Years
7.62%
0%
7.62%
4 Years
22.25%
0%
22.25%
5 Years
6.46%
0%
6.46%
Hubei Guangji Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.51%
EBIT Growth (5y)
-237.28%
EBIT to Interest (avg)
0.62
Debt to EBITDA (avg)
6.37
Net Debt to Equity (avg)
0.74
Sales to Capital Employed (avg)
0.28
Tax Ratio
1.66%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.71%
ROE (avg)
2.78%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.90
EV to EBIT
-12.68
EV to EBITDA
-60.32
EV to Capital Employed
1.49
EV to Sales
4.41
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-11.78%
ROE (Latest)
-28.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
131.40
113.10
16.18%
Operating Profit (PBDIT) excl Other Income
12.20
-2.90
520.69%
Interest
16.50
19.80
-16.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-42.10
-60.90
30.87%
Operating Profit Margin (Excl OI)
-218.40%
-385.80%
16.74%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 16.18% vs -49.91% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 30.87% vs -452.02% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
623.20
724.10
-13.93%
Operating Profit (PBDIT) excl Other Income
-51.50
-16.70
-208.38%
Interest
62.40
50.40
23.81%
Exceptional Items
-27.90
0.80
-3,587.50%
Consolidate Net Profit
-315.10
-152.40
-106.76%
Operating Profit Margin (Excl OI)
-350.80%
-131.70%
-21.91%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -13.93% vs -7.65% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -106.76% vs -419.50% in Dec 2023
About Hubei Guangji Pharmaceutical Co., Ltd. 
Hubei Guangji Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






